The first few days after orthopedic surgery are when many injured workers receive their first opioid prescription, and research has long linked early opioid exposure in workers’ compensation claims to longer disability and higher claim costs. That makes any treatment that controls post-surgical pain without opioids worth watching for adjusters, utilization reviewers and attorneys.
On October 19, 2026, TLC BioSciences, a company based in Taipei and South San Francisco, announced positive topline results from a pivotal Phase 3 trial of TLC590, an injectable, extended-release local anesthetic. In patients recovering from bunion surgery, a single dose reduced pain and opioid use compared with both a placebo and Exparel, the long-acting local anesthetic that is now the market leader in this category.
A local anesthetic numbs the tissue where it is injected. Surgeons commonly infiltrate the surgical site with one at the end of an operation, but standard formulations wear off within hours, which is often when patients reach for opioids. Extended-release products are designed to stretch that numbing effect across the first several days, the period of most intense post-surgical pain.
TLC590 uses ropivacaine, a widely used anesthetic, packaged in the company’s proprietary liposomes, tiny fat-based particles that form a depot at the injection site and release the drug slowly. Exparel, made by Pacira BioSciences, uses a similar liposomal approach with a different drug, bupivacaine. TLC has long pointed to earlier research finding that ropivacaine carries less cardiovascular and central nervous system toxicity than bupivacaine, though the new announcement makes no safety comparison beyond reporting similar side-effect profiles. The product has been in development for years; TLC began human trials in hernia repair patients in 2018 and moved to bunion surgery with a Phase 2 study in 2019.
The Phase 3 trial, registered as NCT07222748, enrolled 304 adults at U.S. sites who underwent bunionectomy, a surgery to correct a bony deformity at the base of the big toe that involves cutting and fixing bone. Patients were randomly assigned in equal numbers to TLC590 (100 patients), Exparel (102) or saline placebo (102), with neither patients nor investigators knowing which they received. Bunion surgery is a standard testing ground for post-surgical pain drugs because it is reliably painful and fairly uniform from patient to patient.
According to the company, TLC590 met the trial’s primary goal, significantly reducing cumulative pain with movement over the first 72 hours compared with placebo (p=0.0024), and patients also used significantly fewer rescue opioids during that period (p=0.0109). In the head-to-head comparison, TLC590 was statistically superior to Exparel on both cumulative pain (p=0.0202) and opioid consumption (p=0.0177). The company reported that the pain advantage over both comparators held through 168 hours, or seven days. It described TLC590 as generally well tolerated, with a safety profile similar to placebo and Exparel and no drug-related serious adverse events.
TLC chief executive George Yeh called the results a potential “paradigm shift in postsurgical care,” and a trial investigator said the data suggest pain control through the first postoperative week with less reliance on opioids. The company said it will complete the full analysis and prepare a New Drug Application to the U.S. Food and Drug Administration.
Several cautions apply. These are topline results announced by the drug’s maker in a press release; they have not been peer reviewed or published, and the release reports p-values without the actual pain scores or opioid amounts in each group, so the size of the advantage cannot yet be judged. Statistical significance is not the same as a difference patients would notice. The study covered one procedure in relatively healthy adults, and the eligibility criteria excluded patients with positive urine drug screens, a group that is not rare among injured workers with chronic pain. TLC590 is not approved, and any FDA label would initially be tied to the evidence submitted.
TLC590 joins a broader push toward non-opioid pain control that already includes Exparel and Vertex’s oral drug Journavx (suzetrigine). The next milestones are publication of the full trial data, the FDA submission and review, and results in other surgical models; the company has run a separate Phase 2 study that includes total knee replacement. Pricing will matter as much as performance for payers. Claims professionals should treat the current results as promising but preliminary, and look for peer-reviewed data on opioid reduction, function and return to work before treating this or any extended-release anesthetic as a cost saver.